SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Sympos
SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Symposium. Daniel Petrylak MD of Yale University Medical Center in New Haven CT discussed the clinical potential arising from his group’s study findings: anti-tumor activity and responses of PSA and circulating tumour cells arising from treatment with an immunoconjugate consisting of an antibody to prostate specific membrane antigen bonded to the microtubule-disrupting molecule monomethyl auristatin E (MMAE).
CONTACT:
Daniel Peter Petrylak MD, Yale University Medical Center, New Haven, CT SOURCE:
Abstract No: 8
ABSTRACT TITLE: A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
LINK:
Abstract web link: http://abstracts.asco.org/142/AbstView_142_124080.html
Related Episodes
Which High-Risk Prostate Cancers Need Multimodality Treatment?
MILAN, Italy—Patients with node-positive prostate cancer being treated with prostatectomy could derive benefit from early multimodality therapy combining androgen deprivation therapy (ADT) with radiot
Gene Assay Predicts Which Patients Need Radiation After Prostatectomy
ARTICLE MILAN, Italy—Genomic testing combined with clinical assessment could be the best way to identify patients with prostate cancer who can benefit from early radiotherapy after prostatectomy, acco